Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat

Journal of NeuroVirology

Volumn 16, Issue 2, 2010, Pages 168-173

  Webb, Katy M ^a,b   Aksenov, Michael Y ^b   MacTutus, Charles F ^b   Booze, Rosemarie M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine; HIV 1; Pediatric; Transgenic

Indexed keywords

DOPAMINE TRANSPORTER; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MESENCEPHALON; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSGENIC RAT;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIV INFECTIONS; HIV-1; MALE; MESENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 77952145741     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550281003690177     Document Type: Article

References (28)

1. Aksenova MV, Silvers JM, Akenov MY, Nath A, Ray PD, Mactutus CF, Booze RM (2006). HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immuno-reactivity. Neurosci Lett 395: 235-239.
2. Albert KA, Helmer-Matyjek E, Nairn AC, Müller TH, Haycock JW, Greene LA, Goldstein M, Greengard P (1984). Calcium/phospholipid-dependent protein kinase (protein kinase C) phosphorylates and activates tyrosine hydroxylase. Proc Natl Acad Sci USA 81: 7713-7717.
3. Biadgilign S, Deribew A, Amberbir A, Deribe K (2008). Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. E-Pub BMC Pediatr 8: 53.
4. Campbell DG, Hardie DG, Vulliet PR (1986). Identification of four phosphorylation sites in the N-terminal region of tyrosine hydroxylase. J Biol Chem 261: 10489-10492.
5. Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF (1992). Site-directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP dependent phosphorylation on enzyme activity. J Biol Chem 267: 12639-12646.
6. Ferris MJ, Mactutus CF, Booze RM (2008). Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in neuroAIDS. Neurosci Biobehav Rev 32: 883-909.
7. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009a). The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159: 1292-1299.
8. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009b). In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63: 181-185.
9. Fitting S, Booze RM, Mactutus CF (2006). Neonatal hippo-campal Tat injections: developmental effects on pre-pulse inhibition (PPI) of the auditory startle response. Int J Dev Neurosci 24: 275-283.
10. Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006). Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1: 410-420
11. Havens JF, Whitaker AH, Feldman JF, Ehrhardt AA (1994). Psychiatric morbidity in school-age children with congenital human immunodeficiency virus infection: a pilot study. J Dev Behav Pediatr 15: S18-25.
12. KieburtzKD,EpsteinLG,GelbardHA,GreenamyreJT(1991). Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol 48: 1281-1284
13. Lashomb A, Vigorito M, Chang SL (2009). Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J NeuroVirol 15: 14-24.
14. Lopez OL, Smith G, Meltzer CC, Becker JT (1999). Dopa-mine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol 12: 184-192
15. Mintz M (1996). Neurological and developmental problems in pediatric HIV infection. J Nutr 126: 2663S-2673S.
16. Mintz M (2005). Clinical features. In: The neurology of AIDS, 2nd ed. Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (eds.). New York: Oxford University Press, pp 639-658.
17. Nagatsu T, Levitt M, Udenfriend S (1964). Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239: 2910-2917.
18. Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, Hayes N, Jones O, Doodnauth D,Davis H, Sill A, O'DriscollP, Huso D, FoutsT, LewisG,HillM, Kamin-Lewis R,WeiC,Ray P, GalloRC, ReitzM,BryantJ(2001).AnHIV-1transgenicrat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci USA 98: 9271-9276.
19. Silvers JM, Aksenov MY, Aksenova MV, Beckley J, Olton P, Mactutus CF, Booze RM (2006). Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J NeuroVirol 12: 140-145.
20. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2007). Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28: 1184-1190
21. Spear LP (2007). Assessment of adolescent neurotoxicity: rationale and methodological considerations. Neuro-toxicol Teratol 29: 1-9.
22. Tzschentke TM (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63: 241-320.
23. UNAIDS (2008). Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS. http://data. unaids.org/pub/GlobalReport/2008/JC1510- 2008Global Report-en.zip.
24. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004). Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452-2458.
25. Webb KM, Mactutus CF, Booze RM (2009). The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy. Expert Rev Anti Infect Ther 7: 93-203
26. Wolters PL, Brouwers P, Civitello L, Moss HA (1997). Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS 11: 1135-1144.
27. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M (2000). HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275: 4159-4165.
28. 3H]2beta- carbomethoxy-3-beta-(4-fluoro-phenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329: 1071-1083.